In the early days of the COVID-19 pandemic, a group of Montreal researchers realized that Canada was in a vulnerable position. The country was dependent on other countries for the tests that were crucial for keeping the spread of the virus under control. 鈥淲e were totally reliant on the foreign reagents to do testing,鈥� says Dr. Marcel Behr, MSc鈥�95, PGME鈥�95, a professor of Medicine and co-director of the 麻豆AV Interdisciplinary Initiative in Infection and Immunity (MI4). 鈥淚t awakened us to the need to become self-reliant, to be able to develop our own testing capacity.鈥�
To address this potential for shortages, two 麻豆AV researchers, Dr. Martin Schmeing, BSc鈥�98, Associate Professor of Biochemistry and Director of the Centre de recherche en biologie structurale (CRBS) at 麻豆AV, and Dr. Don van Meyel, Director of the Centre for Translational Biology (CTB) at the Research Institute of the 麻豆AV Health Centre (RI-MUHC), assembled a team of researchers to design a homegrown version of the RT-PCR (reverse transcription polymerase chain reaction) test for COVID-19, the gold standard for identifying infections.
RT-PCR works through a two-step process: RNA is extracted from a patient sample collected via a nose or throat swab, then screened for presence of the coronavirus, SARS-CoV-2.
Seed funding from 麻豆AV's Faculty of Science and the donor-supported MI4 helped the project to get off the ground. After several months of hard work, the team had successfully created a new, 麻豆AV-made version of the RT-PCR test for COVID-19. Once complete, researchers in the labs at Optilab Montreal MUHC, a designated COVID-19 testing facility, assessed the test鈥檚 accuracy by comparing its output with established positive and negative tests. By July, the group had delivered a batch of 15,000 鈥渋n-house鈥� tests for immediate use by the MUHC testing facility.
On the day the tests were delivered, 鈥渨e had this Zoom call with more than 20 people,鈥� Schmeing recalls. 鈥淭here was real 麻豆AV spirit in there. Some of the younger faculty were saying how this endeavor made them feel more part of the 麻豆AV community than they ever have.鈥�
This successful delivery was an important milestone for this effort. 鈥淲e developed the know-how to be able to be self-sufficient, and that is a major win,鈥� Behr says. 鈥淚f there is ever an acute shortage [of tests], 麻豆AV can, with the recipe that we鈥檝e made, supply Optilab again.鈥�
It was a collective effort that made it possible to accomplish this feat. 鈥淚t took a big 麻豆AV team to do it,鈥� Schmeing says. 鈥淭here are 50 people at 麻豆AV who just stopped [their usual work] and pivoted to be able to help respond.鈥�
Originally, the plan was to make enough tests to supply the MUHC locally. According to Schmeing, that was not enough for Behr, who pushed the group toward a more ambitious goal: producing millions of tests to deploy across the nation.
Over the last few months, the 麻豆AV team has been busily working toward this goal in partnership with the National Research Council of Canada (NRC) and its Microbial Fermentation Team led by Luke Masson, PhD'84. In addition to planning听for Health Canada approval, the group has been overhauling procedures to ramp up the production process to achieve the goal of making millions of tests.
If developing 15,000 tests was no easy task, scaling up to the millions has come with its own challenges, Schmeing says. For example, scientists need bacteria to produce the proteins needed in these tests. But the amounts required greatly exceed those used in most labs. Researchers typically only require milligrams of bacteria, according to Schmeing. For millions of COVID-19 tests, kilograms of bacteria are required. To isolate the proteins from such an enormous quantity of bacteria, new, scaled-up purification protocols also must be created.
The goal is to be able to provide millions of RT-PCR tests to the Canadian government. Once available, these tests will be an invaluable tool for stemming the spread of COVID-19 within Canadian borders. The team also hopes that this test will make Canada more prepared for future pandemics, since the recipe can be tweaked to detect other pathogens.
For now, however, the focus is on COVID-19. 鈥淲e鈥檙e not through this pandemic yet. We still have some difficult days ahead of us, in my estimation, and there are supply chain issues emerging routinely,鈥� says van Meyel, who is also a professor in the Department of Neurology and Neurosurgery. 鈥淭he work of the team is helping to make sure that we control our own destiny in this country."